CA
VYGR icon

CoreCap Advisors’s Voyager Therapeutics VYGR Stock Holding History

CoreCap Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-550
Closed -$2.12K – 3287
2026
Q1 		$2.12K Hold
550
– – ﹤0.01% 2399
2025
Q4 		$2.16K Hold
550
– – ﹤0.01% 2459
2025
Q3 		$2.57K Hold
550
– – ﹤0.01% 2330
2025
Q2 		$1.71K Hold
550
– – ﹤0.01% 2338
2025
Q1 		$1.86K Hold
550
– – ﹤0.01% 2376
2024
Q4 		$3.12K Hold
550
– – ﹤0.01% 2105
2024
Q3 		$3.22K Hold
550
– – ﹤0.01% 2084
2024
Q2 		$4.35K Hold
550
– – ﹤0.01% 1194
2024
Q1 		$5.12K Buy
+550
New +$4.64K ﹤0.01% 1908

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CoreCap Advisors's VYGR Position: Q2 2026 in Review

CoreCap Advisors sold out of Voyager Therapeutics (VYGR) in Q2 2026, closing a stake of 550 shares — an estimated $2.12K sold.

CoreCap Advisors first reported a position in VYGR in Q1 2024 and held it in 9 quarters. The position peaked at $5.12K in Q1 2024. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • CoreCap Advisors reported no remaining Voyager Therapeutics position as of Q2 2026 after selling out during the quarter.
  • CoreCap Advisors sold 550 Voyager Therapeutics shares in Q2 2026, an estimated $2.12K.
  • CoreCap Advisors first reported a position in Voyager Therapeutics in Q1 2024 and held it in 9 quarters.
  • CoreCap Advisors's Voyager Therapeutics position peaked at $5.12K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.